Quarterly report · Q2
4626.TEDINET S100PGNK
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥52.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥98.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥198.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥189.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥184.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥103.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥93.4bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥85.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥57.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥51.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥54.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥18.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥133.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.13 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.84 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥63.83 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 47.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥10.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.0bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥52.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥48.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)PwCあらた有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)齊藤 剛 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)尻引 善博 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 48348000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 52795000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 97966000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 9505000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 10203000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 18062000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 6717000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 7489000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 11803000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 7440000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 10181000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 15611000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 81509000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 93379000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 85466000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 184031000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 198409000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 189273000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 118.84 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 133.32 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 209.13 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.441 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.471 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.452 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 8528000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 12600000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 18308000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -6677000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -4456000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -11258000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -4693000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -2929000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -11279000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 51572000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 57245000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 51152000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 63.83 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 68.86 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 58185501 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 58185501 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 58185501 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 58185501 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |